RE: Patent lives24 Mar 2021 11:36
Tue, 19th Jan 2021 07:00
RNS Number : 0820M
ValiRx PLC
19 January 2021
19 January 2021
("ValiRx", the "Company" or the "Group")
Patent Status Update
Notification of allowance of VAL201 for the treatment of metastatic cancer
and four other patents granted
London, UK - ValiRx plc ("ValiRx", AIM:VAL), a clinical stage drug development company, announces that its patent portfolio continued to build in 2020, with four patents granted during the last 12 months (see table below).
Additionally, in January 2021, the European Patent Office notified the Company of its intention to grant a patent which extends patent cover for VAL201 into metastatic cancer. These statements of protection are similar to those granted by the US patent office announced in November 2019 and creates a broad coverage of use of the peptide in an important area of oncology.
The patents granted during 2020 and the notice received by the European Patent Office in relation to VAL201 can be found below: